把三张表、经营指标、SEC / 巨潮 / 港交所原始财报、业绩材料和电话会放到同一条可核验时间线上。 披露事实、结构化补位值与派生指标分开标注，缺失逐字稿不会用摘要或模型生成内容补齐。
单季、累计、年度和资产负债表时点分开保存；每个数值都保留单位、申报日、表单、XBRL 概念或原始中文字段。
美股链接 SEC 法定申报和发行人 IR，A 股链接巨潮原始 PDF，港股链接港交所披露易原始年报与中报。分部、订单、产能和客户集中度只在有可核验披露时展示。
官方电话会入口与已授权逐字稿分开。没有合法取得的全文时只显示材料可用性，不生成或拼接虚假的逐字稿。
三张表会执行资产负债、毛利润、税前利润等勾稽检查；超出容差的记录保留原值并标记警告， 不会为了让公式“对上”而修改公司披露。
| 2026-06-30 |
| 3/3 |
| $32.61M |
| $3.31M |
| -$8.41M |
| 65.1% |
| 9.1% |
| 74 |
| 尚无授权文本 |
| ASPS ALTISOURCE PORTFOLIO SOLUTIONS S.A. | 2026-06-30 | 3/3 | $50.66M | -$515,000 | -$2.55M | 25.3% | 2.2% | 100 | 尚无授权文本 |
| BCYC BICYCLE THERAPEUTICS PLC | 2026-06-30 | 3/3 | $629,000 | -$50.33M | -$116.51M | — | -8673.9% | 102 | 尚无授权文本 |
| CCC CCC Intelligent Solutions Holdings Inc. | 2026-06-30 | 3/3 | $285.93M | $20.79M | $124.03M | 73.7% | 16.7% | 98 | 尚无授权文本 |
| CLMB Climb Global Solutions, Inc. | 2026-06-30 | 3/3 | $174.21M | $5.52M | $31.26M | 17.3% | 4.2% | 92 | 尚无授权文本 |
| CORT CORCEPT THERAPEUTICS INC | 2026-06-30 | 3/3 | $256.15M | $42.99M | $14.04M | 98.4% | 16.1% | 85 | 尚无授权文本 |
| CTNM Contineum Therapeutics, Inc. | 2026-06-30 | 3/3 | — | -$15.15M | -$28.09M | — | — | 35 | 尚无授权文本 |
| DFIN Donnelley Financial Solutions, Inc. | 2026-06-30 | 3/3 | $224.2M | $36.4M | $45.2M | — | 25.0% | 68 | 尚无授权文本 |
| DYN Dyne Therapeutics, Inc. | 2026-06-30 | 3/3 | — | -$178.56M | -$276.94M | — | — | 88 | 尚无授权文本 |
| FULC Fulcrum Therapeutics, Inc. | 2026-06-30 | 3/3 | — | -$26.18M | -$34.91M | — | — | 94 | 尚无授权文本 |
| IONS IONIS PHARMACEUTICALS INC | 2026-06-30 | 3/3 | $267.95M | -$114.65M | -$265.13M | 99.0% | -38.2% | 120 | 尚无授权文本 |
| MAIR Madison Air Solutions Corp | 2026-06-30 | 3/3 | $991.3M | $69.2M | $139.9M | 39.0% | 19.7% | 7 | 尚无授权文本 |
| MDGL MADRIGAL PHARMACEUTICALS, INC. | 2026-06-30 | 3/3 | $364.25M | -$57.94M | -$152.21M | — | -15.5% | 87 | 尚无授权文本 |
| PHAT Phathom Pharmaceuticals, Inc. | 2026-06-30 | 3/3 | $74.27M | -$17.58M | -$17.68M | 79.7% | -5.3% | 113 | 尚无授权文本 |
| PTCT PTC THERAPEUTICS, INC. | 2026-06-30 | 3/3 | $360.52M | $83.5M | $66.68M | — | 41.3% | 107 | 尚无授权文本 |
| REGN REGENERON PHARMACEUTICALS, INC. | 2026-06-30 | 3/3 | $4.29B | $1.3B | — | — | 30.1% | 82 | 尚无授权文本 |
| SMMT Summit Therapeutics Inc. | 2026-06-30 | 3/3 | — | -$215.7M | -$264.57M | — | — | 145 | 尚无授权文本 |
| TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD | 2026-06-30 | 3/3 | $4.14B | -$576M | — | 52.0% | -5.6% | 84 | 尚无授权文本 |
| VKTX Viking Therapeutics, Inc. | 2026-06-30 | 3/3 | $0 | -$128.02M | — | — | — | 70 | 尚无授权文本 |
| WST WEST PHARMACEUTICAL SERVICES INC | 2026-06-30 | 3/3 | $872.3M | $154M | $128M | 37.7% | 20.5% | 77 | 尚无授权文本 |
| NRIX Nurix Therapeutics, Inc. | 2026-05-31 | 3/3 | $9.04M | -$89.54M | -$171.47M | — | -1041.7% | 102 | 尚无授权文本 |
| PENG Penguin Solutions, Inc. | 2026-05-29 | 3/3 | $478.71M | $44.69M | $3.93M | 27.8% | 10.6% | 102 | 尚无授权文本 |
| BCTX BriaCell Therapeutics Corp. | 2026-04-30 | 3/3 | — | -$7.16M | -$22.82M | — | — | 133 | 尚无授权文本 |
| ENGN enGene Therapeutics Inc. | 2026-04-30 | 3/3 | — | -$30.23M | -$59.65M | — | — | 53 | 尚无授权文本 |
| SYPR SYPRIS SOLUTIONS INC | 2026-04-05 | 3/3 | — | -$4.13M | -$2.57M | — | — | 70 | 尚无授权文本 |
| MSI Motorola Solutions, Inc. | 2026-04-04 | 3/3 | $2.71B | $366M | — | 50.2% | 19.3% | 88 | 尚无授权文本 |
| MTSI MACOM Technology Solutions Holdings, Inc. | 2026-04-03 | 3/3 | $288.96M | $46.33M | $95.46M | 56.9% | 17.6% | 69 | 尚无授权文本 |
| SWKS SKYWORKS SOLUTIONS, INC. | 2026-04-03 | 3/3 | $943.7M | $35.6M | $306.9M | 40.8% | 4.5% | 89 | 尚无授权文本 |
| AARD Aardvark Therapeutics, Inc. | 2026-03-31 | 3/3 | — | -$21.59M | — | — | — | 26 | 尚无授权文本 |
| ABEO ABEONA THERAPEUTICS INC. | 2026-03-31 | 3/3 | $8.72M | -$17.08M | -$20.74M | 69.1% | -264.1% | 111 | 尚无授权文本 |
| ABOS Acumen Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | — | -$20.74M | — | — | — | 72 | 尚无授权文本 |
| ACAD ACADIA PHARMACEUTICALS INC | 2026-03-31 | 3/3 | $268.06M | $3.64M | $28.77M | 90.8% | -1.7% | 83 | 尚无授权文本 |
| ACRS Aclaris Therapeutics, Inc. | 2026-03-31 | 3/3 | $2M | -$19.82M | -$18.16M | 80.2% | -1111.8% | 97 | 尚无授权文本 |
| ACRV Acrivon Therapeutics, Inc. | 2026-03-31 | 3/3 | — | -$19.04M | -$20.55M | — | — | 57 | 尚无授权文本 |
| ACTU ACTUATE THERAPEUTICS, INC. | 2026-03-31 | 3/3 | — | -$5.63M | — | — | — | 27 | 尚无授权文本 |
| ACXP Acurx Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | — | -$1.68M | — | — | — | 56 | 尚无授权文本 |
| ADCT ADC Therapeutics SA | 2026-03-31 | 3/3 | $20.03M | -$32.97M | -$29.74M | — | -126.0% | 168 | 尚无授权文本 |
| ADIL ADIAL PHARMACEUTICALS, INC. | 2026-03-31 | 3/3 | — | -$2.02M | — | — | — | 145 | 尚无授权文本 |
| ADV Advantage Solutions Inc. | 2026-03-31 | 3/3 | $869.6M | -$71.83M | — | — | 0.5% | 102 | 尚无授权文本 |
| AESI Atlas Energy Solutions Inc. | 2026-03-31 | 3/3 | $265.58M | -$47.26M | -$10.28M | 2.4% | -12.2% | 53 | 尚无授权文本 |
| AKBA Akebia Therapeutics, Inc. | 2026-03-31 | 3/3 | $53.54M | -$9.05M | -$21.27M | 77.0% | -8.8% | 128 | 尚无授权文本 |
| AKTX Akari Therapeutics Plc | 2026-03-31 | 3/3 | — | -$14.46M | — | — | — | 135 | 尚无授权文本 |
| ALDX Aldeyra Therapeutics, Inc. | 2026-03-31 | 3/3 | — | -$3.45M | — | — | — | 103 | 尚无授权文本 |
| ALGS Aligos Therapeutics, Inc. | 2026-03-31 | 3/3 | $2.83M | -$23.04M | — | — | -951.6% | 76 | 尚无授权文本 |
| ALLO Allogene Therapeutics, Inc. | 2026-03-31 | 3/3 | — | -$42.61M | -$12.92M | — | — | 88 | 尚无授权文本 |
| ALLR Allarity Therapeutics, Inc. | 2026-03-31 | 3/3 | — | -$2.75M | -$4.56M | — | — | 167 | 尚无授权文本 |
| AMLX Amylyx Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | — | -$41.28M | — | — | — | 68 | 尚无授权文本 |
| AMPH Amphastar Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | $171.17M | $6.42M | $38.33M | 41.1% | 8.0% | 81 | 尚无授权文本 |
| AMRX Amneal Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | $722.52M | $62.26M | -$34.92M | 44.3% | 19.6% | 86 | 尚无授权文本 |
| ANIP ANI PHARMACEUTICALS INC | 2026-03-31 | 3/3 | $237.46M | $29.49M | $52.3M | — | 16.4% | 115 | 尚无授权文本 |
| ANSC Agriculture & Natural Solutions Acquisition Corp | 2026-03-31 | 3/3 | — | $2.76M | — | — | — | 23 | 尚无授权文本 |
| ANSCU Agriculture & Natural Solutions Acquisition Corp | 2026-03-31 | 3/3 | — | $2.76M | — | — | — | 23 | 尚无授权文本 |
| ANTX AN2 Therapeutics, Inc. | 2026-03-31 | 3/3 | — | -$10.03M | — | — | — | 56 | 尚无授权文本 |
| APGE Apogee Therapeutics, Inc. | 2026-03-31 | 3/3 | — | -$74.11M | — | — | — | 49 | 尚无授权文本 |
| APRE Aprea Therapeutics, Inc. | 2026-03-31 | 3/3 | — | -$3.29M | — | — | — | 107 | 尚无授权文本 |
| APUS Apimeds Pharmaceuticals US, Inc. | 2026-03-31 | 3/3 | — | -$35.06M | -$2.08M | — | — | 24 | 尚无授权文本 |
| APVO Aptevo Therapeutics Inc. | 2026-03-31 | 3/3 | — | -$6.7M | — | — | — | 135 | 尚无授权文本 |
| AQST Aquestive Therapeutics, Inc. | 2026-03-31 | 3/3 | $14.45M | -$8.06M | -$14.86M | 76.0% | -29.1% | 163 | 尚无授权文本 |
| ARCT Arcturus Therapeutics Holdings Inc. | 2026-03-31 | 3/3 | $2.06M | -$26.96M | -$19.44M | — | -1403.7% | 98 | 尚无授权文本 |
| ARMP Armata Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | — | -$115.35M | -$5.85M | — | — | 97 | 尚无授权文本 |
| ARQT Arcutis Biotherapeutics, Inc. | 2026-03-31 | 3/3 | $105.4M | -$11.3M | $2.24M | 90.7% | -8.6% | 91 | 尚无授权文本 |
| ARTV Artiva Biotherapeutics, Inc. | 2026-03-31 | 3/3 | — | -$23.52M | -$21.19M | — | — | 27 | 尚无授权文本 |
| ARWR ARROWHEAD PHARMACEUTICALS, INC. | 2026-03-31 | 3/3 | $73.74M | -$132.73M | $93.21M | — | -191.6% | 86 | 尚无授权文本 |
| ATNM Actinium Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | — | -$5.52M | -$5.87M | — | — | 46 | 尚无授权文本 |
| ATOS ATOSSA THERAPEUTICS, INC. | 2026-03-31 | 3/3 | — | -$9.59M | -$9.58M | — | — | 102 | 尚无授权文本 |
| ATRA Atara Biotherapeutics, Inc. | 2026-03-31 | 3/3 | $516,000 | -$4.15M | — | — | -652.9% | 109 | 尚无授权文本 |
| AUPH Aurinia Pharmaceuticals Inc. | 2026-03-31 | 3/3 | $77.71M | $34.36M | — | 91.6% | 53.3% | 91 | 尚无授权文本 |
| AUTL Autolus Therapeutics plc | 2026-03-31 | 3/3 | $26.22M | -$71.6M | -$68.01M | 6.3% | -227.0% | 90 | 尚无授权文本 |
| AVIR Atea Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | — | -$45.44M | — | — | — | 63 | 尚无授权文本 |
| AVTX Avalo Therapeutics, Inc. | 2026-03-31 | 3/3 | — | -$19.63M | — | — | — | 141 | 尚无授权文本 |
| AXSM Axsome Therapeutics, Inc. | 2026-03-31 | 3/3 | $191.2M | -$64.54M | -$20.82M | — | -33.1% | 147 | 尚无授权文本 |
| BBOT BridgeBio Oncology Therapeutics, Inc. | 2026-03-31 | 3/3 | — | -$42.11M | -$35.94M | — | — | 26 | 尚无授权文本 |
| BCAX Bicara Therapeutics Inc. | 2026-03-31 | 3/3 | — | -$56.21M | -$37.57M | — | — | 25 | 尚无授权文本 |
| BCRX BIOCRYST PHARMACEUTICALS INC | 2026-03-31 | 3/3 | — | -$721.81M | — | — | — | 132 | 尚无授权文本 |
| BDTX Black Diamond Therapeutics, Inc. | 2026-03-31 | 3/3 | — | -$9.04M | — | — | — | 81 | 尚无授权文本 |
| BEAM Beam Therapeutics Inc. | 2026-03-31 | 3/3 | $31.74M | -$94.32M | -$130.75M | — | -337.8% | 88 | 尚无授权文本 |
| BEBE TGE Value Creative Solutions Corp | 2026-03-31 | 3/3 | — | $1.11M | — | — | — | 5 | 尚无授权文本 |
| BGMS Bio Green Med Solution, Inc. | 2026-03-31 | 3/3 | $743,000 | -$197,000 | -$279,000 | — | -33.1% | 136 | 尚无授权文本 |
| BLFS BIOLIFE SOLUTIONS INC | 2026-03-31 | 3/3 | — | $1.19M | -$658,000 | — | — | 96 | 尚无授权文本 |
| BMRN BIOMARIN PHARMACEUTICAL INC | 2026-03-31 | 3/3 | $766.21M | $105.53M | $199.73M | 74.6% | 16.9% | 91 | 尚无授权文本 |
| BOLT Bolt Biotherapeutics, Inc. | 2026-03-31 | 3/3 | $26,000 | -$7.24M | — | — | -29234.6% | 65 | 尚无授权文本 |
| BR BROADRIDGE FINANCIAL SOLUTIONS, INC. | 2026-03-31 | 3/3 | $1.95B | $276.3M | $633.1M | 32.1% | 18.4% | 124 | 尚无授权文本 |
| BRNS Barinthus Biotherapeutics plc. | 2026-03-31 | 3/3 | — | -$5.53M | -$3.37M | — | — | 74 | 尚无授权文本 |
| BTAI BioXcel Therapeutics, Inc. | 2026-03-31 | 3/3 | $206,000 | -$12.69M | -$11.81M | -37.4% | -4962.6% | 142 | 尚无授权文本 |
| CADL Candel Therapeutics, Inc. | 2026-03-31 | 3/3 | — | -$8.86M | -$18.71M | — | — | 102 | 尚无授权文本 |
| CAMP Camp4 Therapeutics Corp | 2026-03-31 | 3/3 | $1.29M | -$18.33M | -$10.98M | — | -1010.1% | 29 | 尚无授权文本 |
| CAPR CAPRICOR THERAPEUTICS, INC. | 2026-03-31 | 3/3 | — | -$33.94M | -$34.38M | — | — | 93 | 尚无授权文本 |
| CATX Perspective Therapeutics, Inc. | 2026-03-31 | 3/3 | — | -$26.19M | -$38.33M | — | — | 152 | 尚无授权文本 |
| CCCC C4 Therapeutics, Inc. | 2026-03-31 | 3/3 | $6.15M | -$25.13M | -$30.01M | — | -451.6% | 96 | 尚无授权文本 |
| CCSI Consensus Cloud Solutions, Inc. | 2026-03-31 | 3/3 | $88.47M | $24.69M | $38.46M | 80.9% | 42.7% | 58 | 尚无授权文本 |
| CGEM Cullinan Therapeutics, Inc. | 2026-03-31 | 3/3 | — | -$49.66M | — | — | — | 83 | 尚无授权文本 |
| CGTX COGNITION THERAPEUTICS INC | 2026-03-31 | 3/3 | — | -$4.57M | — | — | — | 89 | 尚无授权文本 |
| CLDI Calidi Biotherapeutics, Inc. | 2026-03-31 | 3/3 | — | -$4.11M | — | — | — | 119 | 尚无授权文本 |
| CLDX Celldex Therapeutics, Inc. | 2026-03-31 | 3/3 | $15,000 | -$78.69M | -$67.23M | — | -562900.0% | 71 | 尚无授权文本 |
| CMPX Compass Therapeutics, Inc. | 2026-03-31 | 3/3 | — | -$18.32M | -$17.35M | — | — | 77 | 尚无授权文本 |
| CNSP CNS Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | — | -$4.94M | -$4.65M | — | — | 108 | 尚无授权文本 |
| CNTX Context Therapeutics Inc. | 2026-03-31 | 3/3 | — | -$8.68M | -$11.47M | — | — | 70 | 尚无授权文本 |
| COAG Hemab Therapeutics Holdings, Inc. | 2026-03-31 | 3/3 | — | -$22.69M | -$21.7M | — | — | 4 | 尚无授权文本 |
| COLL COLLEGIUM PHARMACEUTICAL, INC | 2026-03-31 | 3/3 | $193.52M | $14.5M | $56.84M | 60.6% | 16.0% | 94 | 尚无授权文本 |
| COYA Coya Therapeutics, Inc. | 2026-03-31 | 3/3 | $251,147 | -$7.21M | — | — | -3042.1% | 64 | 尚无授权文本 |
| CPIX CUMBERLAND PHARMACEUTICALS INC | 2026-03-31 | 3/3 | $9.13M | -$3.29M | $387,025 | 78.8% | -34.3% | 98 | 尚无授权文本 |
| CPK CHESAPEAKE UTILITIES CORP | 2026-03-31 | 3/3 | $353.1M | $59.3M | -$23.9M | — | 28.2% | 113 | 尚无授权文本 |
| CRBP Corbus Pharmaceuticals Holdings, Inc. | 2026-03-31 | 3/3 | — | -$22.97M | -$25.58M | — | — | 118 | 尚无授权文本 |
| CRNX Crinetics Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | $10.73M | -$127.85M | -$125.52M | 98.1% | -1307.8% | 122 | 尚无授权文本 |
| CRSP CRISPR Therapeutics AG | 2026-03-31 | 3/3 | $1.46M | -$122.93M | -$109.4M | — | -8933.3% | 94 | 尚无授权文本 |
| CRVS Corvus Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | — | -$13.69M | -$10.47M | — | — | 87 | 尚无授权文本 |
| CTMX CytomX Therapeutics, Inc. | 2026-03-31 | 3/3 | $10.26M | -$18.25M | -$25.55M | — | -191.8% | 87 | 尚无授权文本 |
| CTSH COGNIZANT TECHNOLOGY SOLUTIONS CORP | 2026-03-31 | 3/3 | $5.41B | $662M | $198M | — | 15.6% | 68 | 尚无授权文本 |
| CTXR Citius Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | $1.67M | -$28.11M | — | 80.3% | -1931.0% | 137 | 尚无授权文本 |
| CURX Curanex Pharmaceuticals Inc | 2026-03-31 | 3/3 | — | -$3.15M | — | — | — | 14 | 尚无授权文本 |
| CVKD Cadrenal Therapeutics, Inc. | 2026-03-31 | 3/3 | — | -$2.5M | — | — | — | 71 | 尚无授权文本 |
| CYCN Cyclerion Therapeutics, Inc. | 2026-03-31 | 3/3 | $0 | -$3.18M | -$1.24M | — | — | 78 | 尚无授权文本 |
| DCOY Decoy Therapeutics Inc. | 2026-03-31 | 3/3 | — | -$2.22M | — | — | — | 114 | 尚无授权文本 |
| DFTX Definium Therapeutics, Inc. | 2026-03-31 | 3/3 | — | -$77.1M | — | — | — | 138 | 尚无授权文本 |
| DIT AMCON DISTRIBUTING CO | 2026-03-31 | 3/3 | — | -$2.17M | -$7.32M | — | — | 61 | 尚无授权文本 |
| DMAC DiaMedica Therapeutics Inc. | 2026-03-31 | 3/3 | — | -$10.04M | -$9.09M | — | — | 84 | 尚无授权文本 |
| DMRA Damora Therapeutics, Inc. | 2026-03-31 | 3/3 | — | -$27.78M | — | — | — | 63 | 尚无授权文本 |
| DNLI Denali Therapeutics Inc. | 2026-03-31 | 3/3 | — | -$128.45M | -$133.67M | — | — | 97 | 尚无授权文本 |
| DNTH Dianthus Therapeutics, Inc. /DE/ | 2026-03-31 | 3/3 | — | -$40.83M | — | — | — | 89 | 尚无授权文本 |
| DRMA Dermata Therapeutics, Inc. | 2026-03-31 | 3/3 | — | -$1.85M | — | — | — | 94 | 尚无授权文本 |
| DSGN Design Therapeutics, Inc. | 2026-03-31 | 3/3 | $0 | -$17.64M | -$16.43M | — | — | 58 | 尚无授权文本 |
| DSGR Distribution Solutions Group, Inc. | 2026-03-31 | 3/3 | $496M | $382,000 | -$23.72M | 32.9% | 2.7% | 94 | 尚无授权文本 |
| DWTX Dogwood Therapeutics, Inc. | 2026-03-31 | 3/3 | — | -$4.99M | — | — | — | 93 | 尚无授权文本 |
| EBS Emergent BioSolutions Inc. | 2026-03-31 | 3/3 | $156.1M | $6.8M | -$36.2M | 53.9% | 6.7% | 137 | 尚无授权文本 |
| EIKN Eikon Therapeutics, Inc. | 2026-03-31 | 3/3 | — | -$82.96M | -$90.06M | — | — | 7 | 尚无授权文本 |
| ELDN Eledon Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | — | -$39.03M | — | — | — | 84 | 尚无授权文本 |
| ELOX Eloxx Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | — | -$3.75M | — | — | — | 81 | 尚无授权文本 |
| ELTX Elicio Therapeutics, Inc. | 2026-03-31 | 3/3 | — | -$11.82M | — | — | — | 99 | 尚无授权文本 |
| ELUT ELUTIA INC. | 2026-03-31 | 3/3 | — | -$7.47M | -$8.29M | — | — | 105 | 尚无授权文本 |
| ELVN Enliven Therapeutics, Inc. | 2026-03-31 | 3/3 | — | -$23.63M | — | — | — | 75 | 尚无授权文本 |
| EMAT Evolution Metals & Technologies Corp. | 2026-03-31 | 3/3 | $1.88M | -$440.31M | -$5.59M | 23.7% | -833.2% | 87 | 尚无授权文本 |
| ENTA ENANTA PHARMACEUTICALS INC | 2026-03-31 | 3/3 | $17.16M | -$13.09M | -$19.01M | — | -69.1% | 76 | 尚无授权文本 |
| EPM EVOLUTION PETROLEUM CORP | 2026-03-31 | 3/3 | $20.17M | -$8.93M | — | 35.7% | -2.8% | 81 | 尚无授权文本 |
| ERNA Ernexa Therapeutics Inc. | 2026-03-31 | 3/3 | — | -$5.51M | -$2.27M | — | — | 135 | 尚无授权文本 |
| ESI Element Solutions Inc | 2026-03-31 | 3/3 | $840M | $55.9M | -$91.7M | 38.4% | 13.3% | 76 | 尚无授权文本 |
| ETON Eton Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | $24.27M | $1.55M | $7.33M | 60.7% | 9.9% | 138 | 尚无授权文本 |
| EVOX Evolution Global Acquisition Corp | 2026-03-31 | 3/3 | — | $1.95M | — | — | — | 9 | 尚无授权文本 |
| EVOXU Evolution Global Acquisition Corp | 2026-03-31 | 3/3 | — | $1.95M | — | — | — | 9 | 尚无授权文本 |
| EWTX Edgewise Therapeutics, Inc. | 2026-03-31 | 3/3 | — | -$49.01M | -$42.8M | — | — | 69 | 尚无授权文本 |
| FATE FATE THERAPEUTICS INC | 2026-03-31 | 3/3 | $1.3M | -$31.21M | -$31.06M | — | -2540.4% | 81 | 尚无授权文本 |
| FDMT 4D Molecular Therapeutics, Inc. | 2026-03-31 | 3/3 | $3.05M | -$68.76M | — | — | -2416.1% | 86 | 尚无授权文本 |
| FENC FENNEC PHARMACEUTICALS INC. | 2026-03-31 | 3/3 | $15.11M | $201,000 | — | — | -0.8% | 80 | 尚无授权文本 |
| FHTX Foghorn Therapeutics Inc. | 2026-03-31 | 3/3 | $3.27M | -$19.88M | -$25.27M | — | -660.3% | 110 | 尚无授权文本 |
| FIGR Figure Technology Solutions, Inc. | 2026-03-31 | 3/3 | $167.01M | $44.95M | — | — | 25.1% | 17 | 尚无授权文本 |
| FISI FINANCIAL INSTITUTIONS INC | 2026-03-31 | 3/3 | — | $20.99M | $23.04M | — | — | 115 | 尚无授权文本 |
| FLNA FILANA THERAPEUTICS, INC. | 2026-03-31 | 3/3 | — | -$10.33M | — | — | — | 117 | 尚无授权文本 |
| FPS Forgent Power Solutions, Inc. | 2026-03-31 | 3/3 | $378.71M | $18.29M | -$49.42M | 34.6% | 10.4% | 6 | 尚无授权文本 |
| FSI FLEXIBLE SOLUTIONS INTERNATIONAL INC | 2026-03-31 | 3/3 | $8.3M | -$241,420 | -$4.05M | 22.8% | -1.0% | 68 | 尚无授权文本 |
| GALT GALECTIN THERAPEUTICS INC | 2026-03-31 | 3/3 | — | -$5.05M | — | — | — | 93 | 尚无授权文本 |
| GANX Gain Therapeutics, Inc. | 2026-03-31 | 3/3 | — | -$5.61M | — | — | — | 84 | 尚无授权文本 |
| GLUE Monte Rosa Therapeutics, Inc. | 2026-03-31 | 3/3 | — | -$44.5M | -$39.24M | — | — | 69 | 尚无授权文本 |
| GMRS GMR Solutions Inc. | 2026-03-31 | 3/3 | $1.46B | $106.34M | $64.61M | — | 15.0% | 4 | 尚无授权文本 |
| GPCR Structure Therapeutics Inc. | 2026-03-31 | 3/3 | — | -$75.97M | $14.05M | — | — | 48 | 尚无授权文本 |
| GRCE Grace Therapeutics, Inc. | 2026-03-31 | 3/3 | — | -$7.79M | — | — | — | 110 | 尚无授权文本 |
| GYRE GYRE THERAPEUTICS, INC. | 2026-03-31 | 3/3 | $22.52M | -$9.86M | $3M | 94.6% | -41.5% | 126 | 尚无授权文本 |
| HALO HALOZYME THERAPEUTICS, INC. | 2026-03-31 | 3/3 | $376.71M | $150.05M | $176.34M | 79.0% | 49.0% | 99 | 尚无授权文本 |
| HLX HELIX ENERGY SOLUTIONS GROUP INC | 2026-03-31 | 3/3 | $287.95M | -$13.41M | — | 3.1% | -4.6% | 93 | 尚无授权文本 |
| HOWL Werewolf Therapeutics, Inc. | 2026-03-31 | 3/3 | — | -$13.53M | — | — | — | 70 | 尚无授权文本 |
| HRTX HERON THERAPEUTICS, INC. /DE/ | 2026-03-31 | 3/3 | — | -$8.11M | -$1.93M | — | — | 107 | 尚无授权文本 |
| IKT Inhibikase Therapeutics, Inc. | 2026-03-31 | 3/3 | $0 | -$16.38M | -$12.06M | — | — | 86 | 尚无授权文本 |
| INBS INTELLIGENT BIO SOLUTIONS INC. | 2026-03-31 | 3/3 | $1.06M | -$2.86M | -$8.87M | 50.5% | -277.8% | 178 | 尚无授权文本 |
| INDP Indaptus Therapeutics, Inc. | 2026-03-31 | 3/3 | — | -$2.54M | — | — | — | 89 | 尚无授权文本 |
| INDV Indivior Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | $317M | $89M | -$29M | 87.4% | 43.2% | 371 | 尚无授权文本 |
| INKT MiNK Therapeutics, Inc. | 2026-03-31 | 3/3 | — | -$2.74M | — | — | — | 60 | 尚无授权文本 |
| INM InMed Pharmaceuticals Inc. | 2026-03-31 | 3/3 | — | -$2.97M | — | — | — | 188 | 尚无授权文本 |
| INO INOVIO PHARMACEUTICALS, INC. | 2026-03-31 | 3/3 | $0 | -$19.68M | -$21.59M | — | — | 75 | 尚无授权文本 |
| INTS INTENSITY THERAPEUTICS, INC. | 2026-03-31 | 3/3 | — | -$2.43M | — | — | — | 56 | 尚无授权文本 |
| IOVA IOVANCE BIOTHERAPEUTICS, INC. | 2026-03-31 | 3/3 | $71.43M | -$79.05M | -$78.68M | 40.5% | -113.5% | 119 | 尚无授权文本 |
| IPSC Century Therapeutics, Inc. | 2026-03-31 | 3/3 | — | -$21.65M | -$25.85M | — | — | 91 | 尚无授权文本 |
| IRWD IRONWOOD PHARMACEUTICALS INC | 2026-03-31 | 3/3 | $106.51M | $40.77M | — | — | 68.1% | 87 | 尚无授权文本 |
| ISSC INNOVATIVE SOLUTIONS & SUPPORT INC | 2026-03-31 | 3/3 | — | $3.43M | $7.72M | — | — | 89 | 尚无授权文本 |
| IVDA Iveda Solutions, Inc. | 2026-03-31 | 3/3 | $1.49M | -$532,831 | — | 33.1% | -37.9% | 46 | 尚无授权文本 |
| JANX Janux Therapeutics, Inc. | 2026-03-31 | 3/3 | — | -$24.36M | -$12.61M | — | — | 68 | 尚无授权文本 |
| JAZZ Jazz Pharmaceuticals plc | 2026-03-31 | 3/3 | $1.07B | $293.1M | $388.5M | — | 31.5% | 100 | 尚无授权文本 |
| JSPR Jasper Therapeutics, Inc. | 2026-03-31 | 3/3 | — | -$1.17M | — | — | — | 101 | 尚无授权文本 |
| KITT Nauticus Robotics, Inc. | 2026-03-31 | 3/3 | $159,575 | -$9.27M | — | — | -3562.0% | 127 | 尚无授权文本 |
| KLRA Kailera Therapeutics, Inc. | 2026-03-31 | 3/3 | — | -$78.87M | — | — | — | 3 | 尚无授权文本 |
| KLRS Kalaris Therapeutics, Inc. | 2026-03-31 | 3/3 | — | -$10.86M | — | — | — | 94 | 尚无授权文本 |
| KNSA Kiniksa Pharmaceuticals International, plc | 2026-03-31 | 3/3 | $214.27M | $22.59M | $50.04M | 90.3% | 13.7% | 80 | 尚无授权文本 |
| KPRX KIORA PHARMACEUTICALS INC | 2026-03-31 | 3/3 | — | -$2.42M | -$3.17M | — | — | 104 | 尚无授权文本 |
| KPTI Karyopharm Therapeutics Inc. | 2026-03-31 | 3/3 | $35.07M | -$22.39M | — | — | -76.3% | 104 | 尚无授权文本 |
| KROS Keros Therapeutics, Inc. | 2026-03-31 | 3/3 | $367,000 | -$23.71M | -$3.6M | — | -7051.0% | 167 | 尚无授权文本 |
| KTTA Pasithea Therapeutics Corp. | 2026-03-31 | 3/3 | — | -$2.87M | — | — | — | 57 | 尚无授权文本 |
| KYMR Kymera Therapeutics, Inc. | 2026-03-31 | 3/3 | $34.37M | -$69.23M | -$89.27M | 0.0% | -244.9% | 98 | 尚无授权文本 |
| KYTX Kyverna Therapeutics, Inc. | 2026-03-31 | 3/3 | — | -$39.73M | — | — | — | 49 | 尚无授权文本 |
| LABT Lakewood-Amedex Biotherapeutics Inc. | 2026-03-31 | 3/3 | — | -$923,291 | — | — | — | 4 | 尚无授权文本 |
| LBRX LB PHARMACEUTICALS INC | 2026-03-31 | 3/3 | — | -$19.05M | -$23.32M | — | — | 16 | 尚无授权文本 |
| LCTX Lineage Cell Therapeutics, Inc. | 2026-03-31 | 3/3 | $1.73M | -$4.81M | -$8.13M | — | -440.2% | 98 | 尚无授权文本 |
| LENZ LENZ Therapeutics, Inc. | 2026-03-31 | 3/3 | $1.9M | -$41.49M | -$33.6M | 43.4% | -2321.7% | 76 | 尚无授权文本 |
| LGND LIGAND PHARMACEUTICALS INC | 2026-03-31 | 3/3 | $51.72M | -$13.35M | $48.46M | — | 33.6% | 110 | 尚无授权文本 |
| LRMR Larimar Therapeutics, Inc. | 2026-03-31 | 3/3 | — | -$29.61M | — | — | — | 105 | 尚无授权文本 |
| LSTA LISATA THERAPEUTICS, INC. | 2026-03-31 | 3/3 | $0 | -$4.49M | -$3.08M | — | — | 92 | 尚无授权文本 |
| LXEO Lexeo Therapeutics, Inc. | 2026-03-31 | 3/3 | — | -$20.2M | -$21.18M | — | — | 46 | 尚无授权文本 |
| LXRX LEXICON PHARMACEUTICALS, INC. | 2026-03-31 | 3/3 | $21.1M | -$1.04M | — | 99.5% | -4.7% | 101 | 尚无授权文本 |
| MAZE Maze Therapeutics, Inc. | 2026-03-31 | 3/3 | $20M | -$24.21M | -$39.21M | — | -132.8% | 19 | 尚无授权文本 |
| MCRB Seres Therapeutics, Inc. | 2026-03-31 | 3/3 | $358,000 | -$19.91M | -$16.36M | — | -5839.9% | 95 | 尚无授权文本 |
| MGRX MANGOCEUTICALS, INC. | 2026-03-31 | 3/3 | $67,864 | -$3.4M | — | 42.7% | -4606.8% | 87 | 尚无授权文本 |
| MGX Metagenomi Therapeutics, Inc. | 2026-03-31 | 3/3 | $1.25M | -$23.06M | -$21.2M | — | -1970.1% | 31 | 尚无授权文本 |